Cagrilintide

Dose/route boundary: once-weekly subcutaneous cagrilintide was studied at 0.3-4.5 mg, not the page’s 0.25 mg starting dose.

Participants were randomly assigned (6:1) to subcutaneous self-injections of once-weekly cagrilintide (0·3, 0·6, 1·2, 2·4, or 4·5 mg), once-daily liraglutide 3·0 mg, or volume-matched placebo (for six placebo groups).

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England) · 2021 · PMID 34798060

Evidence scope. Human phase 2 trial in adults with overweight/obesity without diabetes; subcutaneous self-injection once weekly, with up to six weeks of dose escalation.

Mechanism/class: cagrilintide is a long-acting amylin analogue under investigation for weight management.

Cagrilintide is a long-acting amylin analogue under investigation for weight management.

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England) · 2021 · PMID 34798060

Evidence scope. Definitional statement from a human phase 2 trial; it does not establish every receptor-level detail on the page.

Primary safety: gastrointestinal disorders including nausea, constipation, and diarrhea, plus administration-site reactions, were the most frequent adverse events.

The most frequent adverse events were gastrointestinal disorders (eg, nausea, constipation, and diarrhoea) and administration-site reactions.

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England) · 2021 · PMID 34798060

Evidence scope. Human phase 2 trial; adults with overweight/obesity without diabetes; once-weekly SubQ doses 0.3-4.5 mg for 26 weeks.